Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Phase 3positiveadmilparantPositive
AI Analysis
Summary
Bristol Myers Squibb announced that its Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint, with the 60 mg dose demonstrating statistically significant benefit in FVC decline compared to placebo in adults with idiopathic pulmonary fibrosis.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary endpoint at 60 mg dose with statistically significant benefit in absolute change in FVC from baseline to Week 52 compared with placebo
Importance:8/10
Sentiment:
0.80
Phase 3pulmonary fibrosispositive dataprimary endpoint met
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 12, 2026 6:10 PM